Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients

被引:11
作者
Qiu Kui [2 ]
Tian Hui [1 ]
Wang Wei [1 ]
Hu Xiao-peng [1 ]
Li Xiao-bei [1 ]
Gong Li-li [2 ]
Luo Wei [2 ]
Liu Li-hong [2 ]
Zhang Xiao-dong [1 ]
Yin Hang [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Urol, Kidney Transplantat Program, Beijing 100020, Peoples R China
[2] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pharmacol, Beijing 100020, Peoples R China
关键词
enteric-coated mycophenolate sodium; pharmacokinetics; limited sampling strategy; Chinese renal transplant recipients; LIMITED SAMPLING STRATEGIES; GASTROINTESTINAL INTOLERANCE; ACID EXPOSURE; MPA EXPOSURE; MOFETIL; KIDNEY; BIOEQUIVALENCE; PERFORMANCE; VALIDATION; EFFICACY;
D O I
10.3760/cma.j.issn.0366-6999.2012.23.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Mycophenolic acid (MPA) as an anti-proliferative immune-suppressive agent is used in the majority of immunosuppressive regimens in solid organ transplantation. This study aimed to investigate the pharmacokinetic (PK) characteristics of enteric-coated mycophenolate sodium (EC-MPS) and area under the curve (AUC) from 0 to 12 hours with limited sampling strategies (LSSs) in Chinese renal transplant recipients. Methods This study was conducted in 10 Chinese renal transplant patients receiving living donor and treated with EC-MPS, cyclosporine, and corticosteroids. MPA concentrations were measured by enzyme multiplied immunoassay technique (EMIT). Whole 12-hour PK profiles were obtained on Day 4 after operation. LSSs with jackknife technique, multiple stepwise regression analysis, and Bland-Altman analysis were developed to estimate MPA AUC. Results The mean maximum plasma concentration, the mean time for it to reach peak (T-max), and the mean MPA AUC were (11.38 +/- 2.49) mg/L, (4.85 +/- 3.32) hours, and (63.19 +/- 13.54) mg.h.L-1, respectively. Among the 10 profiles, MPA AUC of four patients was significantly higher than that of the other six patients, and the corresponding T-max was significantly longer than that of the other six patients. No patient exhibited a second peak caused by enterohepatic recirculation. The best models were as follows: 27.46+0.94C(3)+3.24C(8)+2.81C(10) (r(2)=0.972), which was used to predict AUC of fast metabolizer with a mean prediction error (MPE) of -0.21% and a mean absolute prediction error (MAE) of 2.59%; 36.65+3.08C(8)+5.30C(10)-4.04C(12) (r(2)=0.992), which was used to predict AUC of slow metabolizer with a MPE of 0.58% and a MAE of 1.95%. Conclusions The PKs of EC-MPS had a high variability among Chinese renal transplant recipients. The preliminary PK data indicated the existence of slow and fast metabolizer. These findings may be associated with the enterohepatic recirculation. Chin Med J 2012;125(23):4226-4232
引用
收藏
页码:4226 / 4232
页数:7
相关论文
共 23 条
  • [1] Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil
    Arns, W
    Breuer, S
    Choudhury, S
    Taccard, G
    Lee, J
    Binder, V
    Roettele, J
    Schmouder, R
    [J]. CLINICAL TRANSPLANTATION, 2005, 19 (02) : 199 - 206
  • [2] Validation of Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure During the First Year After Heart Transplantation
    Baraldo, M.
    Cojutti, P. G.
    Isola, M.
    Feruglio, M. T.
    Tursi, V.
    Livi, U.
    Furlanut, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4277 - 4284
  • [3] Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration
    Bullingham, R
    Monroe, S
    Nicholls, A
    Hale, M
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (04) : 315 - 324
  • [4] Capone D, 2011, NEPHROL DIAL TRANSPL, V9, P1
  • [5] Pharmacokinetics of mycophenolate sodium and comparison with the mofetil transplant recipients formulation in stable kidney
    Cattaneo, Dario
    Cortinovis, Monica
    Baldelli, Sara
    Bitto, Alessandra
    Gotti, Eliana
    Remuzzi, Giuseppe
    Perico, Norberto
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (06): : 1147 - 1155
  • [6] Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus
    Djabarouti, Sarah
    Duffau, Pierre
    Lazaro, Estibaliz
    Chapouly, Candice
    Greib, Carine
    Viallard, Jean-Francois
    Pellegrin, Jean-Luc
    Saux, Marie-Claude
    Breilh, Dominique
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (05) : 689 - 699
  • [7] Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil
    Fructuoso, A. Sanchez
    Calvo, N.
    Moreno, M. A.
    Giorgi, M.
    Conesa, J.
    Barrientos, A.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2194 - 2196
  • [8] Renal function of donors and recipients after living donor kidney transplantation in a Chinese cohort
    Gong Nian-qiao
    Ming Chang-sheng
    Zeng Fan-jun
    Zhang Wei-jie
    Lin Zhen-bin
    Zhou Ping
    Chen Xiao-ping
    Chen Zhi-shui
    [J]. CHINESE MEDICAL JOURNAL, 2011, 124 (09) : 1290 - 1295
  • [9] Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay
    Hosotsubo, H
    Takahara, S
    Imamura, R
    Kyakuno, M
    Tanaka, T
    Yazawa, K
    Hanafusa, T
    Matsumiya, K
    Nonomura, N
    Okuyama, A
    Sugimoto, H
    [J]. THERAPEUTIC DRUG MONITORING, 2001, 23 (06) : 669 - 674
  • [10] Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies
    Jiao, Zheng
    Zhong, Jian-yong
    Zhang, Ming
    Shi, Xiao-jin
    Yu, Yun-qiu
    Lu, Wei-yue
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (01) : 27 - 37